Stock Analiz

Kyntra Bio, Inc. KYNB

Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026

$3.44Market cap $14M
Open the interactive analysis →

Kyntra Bio, Inc. (KYNB) is a healthcare company listed in the US with a market value of about $14M. In the twelve months to June 30, 2026 it had revenue of $5M and net income of $183M, a net margin of 3967.8%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is track record (0/5).

Key numbers: a P/E of 0.1, a 5-year average ROIC of -211%.

About Kyntra Bio

Kyntra Bio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $138M in 2014 to $30M in 2024, a decline of about 14.2% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 8% over three years (dilution for shareholders).

Score: 1.2 / 5

Value2/5
Future growth1/5
Track record0/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)0.1
Forward P/E—
P/FCF—
P/S3.0
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-273.3%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-275.0%
ROIC (5-yr avg.)-210.6%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$5M—$30M$47M$141M$235M$176M$257M$213M$131M$183M
Net income$183M$183M-$48M-$284M-$294M-$290M-$189M-$77M-$86M-$121M-$58M
Free cash flow-$38M-$5M-$138M-$318M-$150M-$87M$78M-$84M-$84M-$75M$6M
EPS (diluted)$45.28$45.37$-11.89$-73.00$-78.50$-78.50$-52.75$-22.25$-25.75$-41.50$-23.25
Net margin3967.8%—-160.6%-607.3%-208.7%-123.2%-107.4%-30.0%-40.6%-92.3%-31.7%
ROIC————-347.5%-73.8%-35.7%-13.6%-13.5%-17.5%-32.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Kyntra Bio’s P/E ratio?

About 0.1, based on the last twelve months of diluted earnings per share.

Does Kyntra Bio pay a dividend?

Not currently.

Is Kyntra Bio a good stock to buy?

We do not give buy or sell advice. Kyntra Bio scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.